Wai Chun Bio-Technology (HKG:0660) expects a consolidated net loss between HK$57 million and HK$62 million for the year ended June 30, wider than HK$10 million logged for the previous fiscal year, a Monday Hong Kong Exchange filing said.
The modified starch and other biochemical products company attributed the expected increase in loss to impairment losses recognized on property, plant, and equipment, and a decrease in gross profits during the reviewing period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.